EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Fibrosis-4 index utility for screening liver fibrosis and its association with degenerative complications in patients with type 2 diabetes mellitus: a monocentric study

Hanae Rachedi, Abdessamad Malki, Alou Moussa Baraya, Nisrine Bouichrat, Siham Rouf, Hanane Latrech

Medicine and Pharmacy Reports · 19.06.2026

DOI: 10.15386/mpr-2954 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medicine and Pharmacy Reports, online erschienen am 19.06.2026. Verfasst von Hanae Rachedi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology-Diabetology and Nutrition, Mohammed VI University Hospital Center, Faculty of Medicine and Pharmacy, University of Mohamm…. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Backgrounds. The fibrosis-4 index is a simple biomarker tool widely recommended to diagnose advanced hepatic fibrosis in patients with type 2 diabetes mellitus (T2DM). The primary aim of this study was to assess liver fibrosis risk among type 2 diabetes mellitus patients using the Fib-4 score, secondary to compare the prevalence of degenerative complications between patients according to Fib-4 index risk, and to evaluate the prevalence of metabolic dysfunction-associated-steatotic liver disease in our population.

Methods

This is a descriptive-analytical cross-sectional study including 600 patients with type 2 diabetes mellitus who were followed at the Endocrinology- Diabetology and Nutrition Department of a university hospital center, for a period of 8 years and 10 months from January 2016 to October 2024.

Results

The mean age in our population was 59±12.8 years. The median duration of diabetes was 6.4 years (1–15 years) with a median HbA1c value of 10.2±2.7%. Overweight and obesity were found in 39.2% and 34.5% of patients respectively, with a mean BMI of 28.2±5.9 kg/m². The median of fibrosis-4 index was 1.09. Sixty-one percent of patients had a low risk of advanced liver fibrosis, 31% had an intermediate risk, and 8% had a high risk to develop an advanced liver fibrosis. Patients with a Fib-4 score ≥1.3 (indicating intermediate to high risk of liver fibrosis) had a statistically significantly higher prevalence of all microvascular complications and ischemic heart disease (p

Schlagwörter

Stichwörter der Autor:innen

degenerative complicationsfibrosis-4 indexliver fibrosismetabolic dysfunction-associated steatotic liver diseasenon-invasive teststype 2 diabetes mellitus

Autor:innen und Institutionen

  • Department of Endocrinology-Diabetology and Nutrition, Mohammed VI University Hospital Center, Faculty of Medicine and Pharmacy, University of Mohammed 1, Oujda, Morocco.
  • Laboratory of Epidemiology, Clinical Research and Public Health, Mohammed VI University Hospital Center, Faculty of Medicine and Pharmacy, University of Mohammed 1, Oujda, Morocco.

Zitieren

APA

Rachedi, H., Malki, A., Baraya, A. M., Bouichrat, N., Rouf, S., & Latrech, H. (2026). Fibrosis-4 index utility for screening liver fibrosis and its association with degenerative complications in patients with type 2 diabetes mellitus: a monocentric study. Medicine and Pharmacy Reports. https://doi.org/10.15386/mpr-2954

Vancouver

Rachedi H, Malki A, Baraya AM, Bouichrat N, Rouf S, Latrech H. Fibrosis-4 index utility for screening liver fibrosis and its association with degenerative complications in patients with type 2 diabetes mellitus: a monocentric study. Medicine and Pharmacy Reports. 2026. doi:10.15386/mpr-2954

BibTeX
@article{Rachedi2026,
  author = {Rachedi, Hanae and Malki, Abdessamad and Baraya, Alou Moussa and Bouichrat, Nisrine and Rouf, Siham and Latrech, Hanane},
  title = {Fibrosis-4 index utility for screening liver fibrosis and its association with degenerative complications in patients with type 2 diabetes mellitus: a monocentric study},
  journal = {Medicine and Pharmacy Reports},
  year = {2026},
  doi = {10.15386/mpr-2954}
}
Kostenlos starten →